Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)
Fast, easy summary view of NICE guidance on 'renal cancer'
NICE does not recommend everolimus as a second treatment for people with advanced renal cell carcinoma.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their lives. Everolimus did not provide enough benefits to patients to justify its high cost, even when the special considerations were applied, so NICE did not recommend it.
- TA219 Everolimus for the second-line treatment of advanced renal cell carcinoma: guidance (web format)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: renal cancer
This page was last updated: 07 February 2014
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA219 Everolimus fel ail driniaeth ar gyfer carsinoma celloedd arennol datblygedig: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.